P53 regulates mesenchymal stem cell-mediated tumor suppression in a tumor microenvironment through immune modulation

Oncogene

Volumn 33, Issue 29, 2014, Pages 3830-3838

  Huang, Y ^a   Yu, P ^a   Li, W ^a   Ren, G ^b   Roberts, A I ^b   Cao, W ^a   Zhang, X ^a   Su, J ^a   Chen, X ^a   Chen, Q ^a   Shou, P ^a   Xu, C ^a   Du, L ^a   Lin, L ^a   Xie, N ^a   Zhang, L ^b   Wang, Y ^a   Shi, Y ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

immunomodulation; iNOS; mesenchymal stem cells; p53

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA CELL; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR PROMOTION;

ANIMALIA; MUS;

ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; IMMUNOMODULATION; INFLAMMATION MEDIATORS; MELANOMA, EXPERIMENTAL; MESENCHYMAL STROMAL CELLS; MICE; MICE, KNOCKOUT; NEOPLASMS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE II; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84904630964     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.355     Document Type: Article

References (77)

1. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-263
2. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52
3. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 70: 523-526
4. Baker S, Markowitz S, Fearon E, Willson J, Vogelstein B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-917
5. Murray-Zmijewski F, Slee EA, Lu X. A complex barcode underlies the heterogeneous response of p53 to stress. Nat Rev Mol Cell Biol 2008; 9: 702-712
6. Hollstein M, Sidransky D, Vogelstein B, Harris CC. P53 mutations in human cancers. Science 1991; 253: 49-53
7. Hodis E, Watson I, Kryukov G, Arold S, Imielinski M, Theurillat J-P.et al.. A landscape of driver mutations in melanoma. Cell 2012; 150: 251-314
8. Stretch J, Gatter K, Ralfkiaer E, Lane D, Harris A. Expression of mutant p53 in melanoma. Cancer Res 1991; 51: 5976-5985
9. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615
10. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1: a001883
11. Yamanishi Y, Boyle DL, Rosengren S, Green DR, Zvaifler NJ, Firestein GS. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci USA 2002; 99: 10025-10030
12. Simelyte E, Rosengren S, Boyle DL, Corr M, Green DR, Firestein GS. Regulation of arthritis by p53: critical role of adaptive immunity. Arthritis Rheum 2005; 52: 1876-1884
13. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G. The p53 family: guardians of maternal reproduction. Nat Rev Mol Cell Biol 2011; 12: 259-265
14. Giono LE, Manfredi JJ. The p53 tumor suppressor participates in multiple cell cycle checkpoints. J Cell Physiol 2006; 209: 13-20
15. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM.et al.. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109: 335-346
16. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63: 2705-2715
17. Tasdemir E, Maiuri MC, Galluzzi L, Vitale I, Djavaheri-Mergny M, DAmelio M.et al.. Regulation of autophagy by cytoplasmic p53. Nat Cell Biol 2008; 10: 676-687
18. Green DR, Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009; 458: 1127-1130
19. Dvorak H. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659
20. Joyce J, Pollard J. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-291
21. Bergfeld S, DeClerck Y. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010; 29: 249-310
22. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ, Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res 2002; 62: 3603-3608
23. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008; 8: 726-762
24. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C.et al.. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Cell Stem Cell 2012; 11: 812-824
25. Kurose K, Gilley K, Matsumoto S, Watson P, Zhou X-P, Eng C. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002; 32: 355-362
26. Matsumoto N, Yoshida T, Yamashita K, Numata Y, Okayasu I. Possible alternative carcinogenesis pathway featuring microsatellite instability in colorectal cancer stroma. Br J Cancer 2003; 89: 707-719
27. Paterson R, Ulbright T, MacLennan G, Zhang S, Pan C-X, Sweeney C.et al.. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer 2003; 98: 1830-1836
28. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter G.et al.. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med 2007; 357: 2543-2551
29. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts A.et al.. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008; 2: 141-191
30. Li W, Ren G, Huang Y, Su J, Han Y, Li J.et al.. Mesenchymal stem cells: a double-edged sword in regulating immune responses. Cell Death Differ 2012; 19: 1505-1513
31. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2001; 2: 907-916
32. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15: 323-350
33. Addadi Y, Moskovits N, Granot D, Lozano G, Carmi Y, Apte R.et al.. p53 status in stromal fibroblasts modulates tumor growth in an SDF1-dependent manner. Cancer Res 2010; 70: 9650-9658
34. Moskovits N, Kalinkovich A, Bar J, Lapidot T, Oren M. p53 Attenuates cancer cell migration and invasion through repression of SDF-1/CXCL12 expression in stromal fibroblasts. Cancer Res 2006; 66: 10671-10677
35. Armesilla-Diaz A, Elvira G, Silva A. p53 regulates the proliferation, differentiation and spontaneous transformation of mesenchymal stem cells. Exp Cell Res 2009; 315: 3598-4208
36. Rodriguez R, Rubio R, Masip M, Catalina P, Nieto A, de la Cueva T.et al.. Loss of p53 induces tumorigenesis in p21-deficient mesenchymal stem cells. Neoplasia (New York, NY) 2009; 11: 397-804
37. Donehower L, Harvey M, Slagle B, McArthur M, Montgomery C, Butel J.et al.. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215-236
38. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower L. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 1995; 9: 305-316
39. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 1989; 9: 3982-3991
40. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW.et al.. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449: 557-563
41. Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nat Protoc 2009; 4: 102-106
42. Zhu H, Guo ZK, Jiang XX, Li H, Wang XY, Yao HY.et al.. A protocol for isolation and culture of mesenchymal stem cells from mouse compact bone. Nat Protoc 2010; 5: 550-560
43. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867
44. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27: 83-117
45. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674
46. Moinfar F, Man YG, Arnould L, Bratthauer GL, Ratschek M, Tavassoli FA. Concurrent and independent genetic alterations in the stromal and epithelial cells of mammary carcinoma: implications for tumorigenesis. Cancer Res 2000; 60: 2562-2566
47. Tuhkanen H, Anttila M, Kosma V-M, Ylä-Herttuala S, Heinonen S, Kuronen A.et al.. Genetic alterations in the peritumoral stromal cells of malignant and borderline epithelial ovarian tumors as indicated by allelic imbalance on chromosome 3p. Int J Cancer 2004; 109: 247-299
48. Hill R, Song Y, Cardiff R, Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-1012
49. Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L.et al.. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 2004; 101: 4966-4971
50. Nishida N, Nagahara M, Sato T, Mimori K, Sudo T, Tanaka F.et al.. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res 2012; 18: 3054-3070
51. Zou W, Zheng H, He TC, Chang J, Fu YX, Fan W. LIGHT delivery to tumors by mesenchymal stem cells mobilizes an effective antitumor immune response. Cancer Res 2012; 72: 2980-2989
52. Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A.et al.. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009; 27: 2614-2623
53. Maffini MV, Soto AM, Calabro JM, Ucci AA, Sonnenschein C. The stroma as a crucial target in rat mammary gland carcinogenesis. J Cell Sci 2004; 117: 1495-1502
54. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F.et al.. Intraepithelial CD8 tumor-infiltrating lymphocytes and a high CD8/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-18543
55. Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M.et al.. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res 2001; 61: 5132-5136
56. Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S.et al.. CD8 tumorinfiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci USA 2007; 104: 3967-3972
57. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-Analysis. Br J Cancer 2011; 105: 93-103
58. Donia M, Ellebaek E, Andersen MH, Straten PT, Svane IM. Analysis of Vdelta1 T cells in clinical grade melanoma-infiltrating lymphocytes. Oncoimmunology 2012; 1: 1297-1304
59. Donia M, Fagone P, Nicoletti F, Andersen RS, Hogdall E, Straten PT.et al.. BRAF inhibition improves tumor recognition by the immune system: potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 2012; 1: 1476-1483
60. Andersen MH, Sorensen RB, Brimnes MK, Svane IM, Becker JC, thor Straten P. Identification of heme oxygenase-1-specific regulatory CD8+ T cells in cancer patients. J Clin Invest 2009; 119: 2245-2256
61. Sharma MD, Hou DY, Liu Y, Koni PA, Metz R, Chandler P.et al.. Indoleamine 2,3-dioxygenase controls conversion of Foxp+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood 2009; 113: 6102-6111
62. Vukmanovic-Stejic M, Zhang Y, Cook JE, Fletcher JM, McQuaid A, Masters JE.et al.. Human CD4 CD25hi Foxp+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest 2006; 116: 2423-2433
63. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P.et al.. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942-949
64. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004; 4: 71-78
65. Hussain S, He P, Subleski J, Hofseth L, Trivers G, Mechanic L.et al.. Nitric oxide is a key component in inflammation-Accelerated tumorigenesis. Cancer Res 2008; 68: 7130-7136
66. Xu W, Liu L, Loizidou M, Ahmed M, Charles I. The role of nitric oxide in cancer. Cell research 2002; 12: 311-331
67. Cassina A, Radi R. Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch Biochem Biophys 1996; 328: 309-316
68. Brown GC, McBride AG, Fox EJ, McNaught KS, Borutaite V. Nitric oxide and oxygen metabolism. Biochem Soc Trans 1997; 25: 901-904
69. Lepoivre M, Fieschi F, Coves J, Thelander L, Fontecave M. Inactivation of ribonucleotide reductase by nitric oxide. Biochem Biophys Res Commun 1991; 179: 442-448
70. Nguyen T, Brunson D, Crespi CL, Penman BW, Wishnok JS, Tannenbaum SR. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992; 89: 3030-3034
71. Brito C, Naviliat M, Tiscornia AC, Vuillier F, Gualco G, Dighiero G.et al.. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J Immunol 1999; 162: 3356-3366
72. Radi R. Nitric oxide, oxidants and protein tyrosine nitration. Proc Natl Acad Sci USA 2004; 101: 4003-4008
73. Suzuki YJ, Carini M, Butterfield DA. Protein carbonylation. Antioxid Redox Signal 2010; 12: 323-325
74. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 1998; 160: 5729-5734
75. Xie K, Huang S, Dong Z, Juang S, Gutman M, Xie Q.et al.. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995; 181: 1333-1343
76. Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC.et al.. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci USA 1996; 93: 2442-2447
77. Miranda KM, Espey MG, Wink DA. A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 2001; 5: 62-71.